[go: up one dir, main page]

WO2019066490A3 - 유전자 발현 조절을 위한 인위적인 게놈 조작 - Google Patents

유전자 발현 조절을 위한 인위적인 게놈 조작 Download PDF

Info

Publication number
WO2019066490A3
WO2019066490A3 PCT/KR2018/011424 KR2018011424W WO2019066490A3 WO 2019066490 A3 WO2019066490 A3 WO 2019066490A3 KR 2018011424 W KR2018011424 W KR 2018011424W WO 2019066490 A3 WO2019066490 A3 WO 2019066490A3
Authority
WO
WIPO (PCT)
Prior art keywords
expression
gene expression
expression regulation
regulating
repeated genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/011424
Other languages
English (en)
French (fr)
Other versions
WO2019066490A2 (ko
Inventor
김석중
송동우
이재영
이정민
조규본
배희숙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toolgen Inc
Original Assignee
Toolgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2020513755A priority Critical patent/JP2020536501A/ja
Priority to RU2020114785A priority patent/RU2767201C2/ru
Priority to CN201880076752.2A priority patent/CN111527208B/zh
Priority to CA3077153A priority patent/CA3077153A1/en
Priority to AU2018339164A priority patent/AU2018339164B2/en
Priority to BR112020006428-9A priority patent/BR112020006428A2/pt
Priority to EP18862957.0A priority patent/EP3690047A4/en
Priority to SG11202002130WA priority patent/SG11202002130WA/en
Priority to CN202410521102.1A priority patent/CN118581083A/zh
Application filed by Toolgen Inc filed Critical Toolgen Inc
Publication of WO2019066490A2 publication Critical patent/WO2019066490A2/ko
Publication of WO2019066490A3 publication Critical patent/WO2019066490A3/ko
Priority to US16/776,707 priority patent/US11572574B2/en
Anticipated expiration legal-status Critical
Priority to JP2021170086A priority patent/JP7440043B2/ja
Priority to US18/147,156 priority patent/US12163149B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 중복 유전자의 발현을 조절하기 위한 발현 조절용 조성물 또는 이를 이용한 방법에 관한 것이다. 보다 구체적으로, 중복 유전자의 전사 조절 영역을 표적화할 수 있는 가이드핵산을 포함하는 발현 조절용 조성물 및 이를 이용한 중복 유전자의 전사 조절 영역을 인위적으로 조작 및/또는 변형시켜 중복 유전자의 발현을 조절하는 방법에 관한 것이다. 또한 중복 유전자의 발현을 조절하기 위한 발현 조절용 조성물을 이용하여 유전자 중복에 의해 발생하는 질환을 치료 또는 개선하는 방법에 관한 것이다.
PCT/KR2018/011424 2017-09-28 2018-09-27 유전자 발현 조절을 위한 인위적인 게놈 조작 Ceased WO2019066490A2 (ko)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN202410521102.1A CN118581083A (zh) 2017-09-28 2018-09-27 用于基因表达调节的人工基因组操纵
CN201880076752.2A CN111527208B (zh) 2017-09-28 2018-09-27 用于基因表达调节的人工基因组操纵
CA3077153A CA3077153A1 (en) 2017-09-28 2018-09-27 Artificial genome manipulation for gene expression regulation
AU2018339164A AU2018339164B2 (en) 2017-09-28 2018-09-27 Artificial genome manipulation for gene expression regulation
BR112020006428-9A BR112020006428A2 (pt) 2017-09-28 2018-09-27 manipulação de genoma artificial para regulação de expressão de genes
EP18862957.0A EP3690047A4 (en) 2017-09-28 2018-09-27 ARTIFICIAL GENOME MANIPULATION FOR GENE EXPRESSION REGULATION
SG11202002130WA SG11202002130WA (en) 2017-09-28 2018-09-27 Artificial genome manipulation for gene expression regulation
JP2020513755A JP2020536501A (ja) 2017-09-28 2018-09-27 遺伝子発現調節のための人為的なゲノム操作
RU2020114785A RU2767201C2 (ru) 2017-09-28 2018-09-27 Искусственная модификация генома для регуляции экспрессии гена
US16/776,707 US11572574B2 (en) 2017-09-28 2020-01-30 Artificial genome manipulation for gene expression regulation
JP2021170086A JP7440043B2 (ja) 2017-09-28 2021-10-18 遺伝子発現調節のための人為的なゲノム操作
US18/147,156 US12163149B2 (en) 2017-09-28 2022-12-28 Artificial genome manipulation for gene expression regulation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762564478P 2017-09-28 2017-09-28
US62/564,478 2017-09-28
US201762565868P 2017-09-29 2017-09-29
US62/565,868 2017-09-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/776,707 Continuation-In-Part US11572574B2 (en) 2017-09-28 2020-01-30 Artificial genome manipulation for gene expression regulation

Publications (2)

Publication Number Publication Date
WO2019066490A2 WO2019066490A2 (ko) 2019-04-04
WO2019066490A3 true WO2019066490A3 (ko) 2019-06-27

Family

ID=65902054

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/011424 Ceased WO2019066490A2 (ko) 2017-09-28 2018-09-27 유전자 발현 조절을 위한 인위적인 게놈 조작

Country Status (10)

Country Link
EP (1) EP3690047A4 (ko)
JP (2) JP2020536501A (ko)
KR (1) KR102670361B1 (ko)
CN (2) CN118581083A (ko)
AU (1) AU2018339164B2 (ko)
BR (1) BR112020006428A2 (ko)
CA (1) CA3077153A1 (ko)
RU (2) RU2022103641A (ko)
SG (1) SG11202002130WA (ko)
WO (1) WO2019066490A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110577972B (zh) * 2019-08-08 2022-10-11 复旦大学 CRISPR/Sa-ShaCas9基因编辑系统及其应用
CN110577970B (zh) * 2019-08-08 2022-11-18 复旦大学 CRISPR/Sa-SlutCas9基因编辑系统及其应用
CN110577969B (zh) * 2019-08-08 2022-07-22 复旦大学 CRISPR/Sa-SlugCas9基因编辑系统及其应用
WO2021145703A1 (ko) * 2020-01-14 2021-07-22 주식회사 툴젠 알츠하이머 예방 또는 치료용 약학적 조성물 및 이의 용도
IL303308A (en) * 2020-12-01 2023-07-01 Res Inst Nationwide Childrens Hospital Products and methods for inhibiting the expression of myelin protein kp-22
WO2022167421A1 (en) * 2021-02-02 2022-08-11 Limagrain Europe Linkage of a distal promoter to a gene of interest by gene editing to modify gene expression
CN114426982B (zh) * 2022-02-22 2024-03-22 上海交通大学 一种细胞代谢重编程的方法及其应用
KR20240034661A (ko) * 2022-09-06 2024-03-14 주식회사 툴젠 캄필로박터 제주니 유래 Cas9의 가이드 RNA 구조변화를 통한 유전자교정 향상 시스템
CN116536357A (zh) * 2023-04-17 2023-08-04 中国医学科学院输血研究所 构建CRISPR/Cas12a中sgRNA剪切活性筛选系统的方法
WO2025079278A1 (ja) * 2023-10-10 2025-04-17 国立大学法人 東京医科歯科大学 シャルコー・マリー・トゥース病の処置剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150101446A (ko) * 2012-10-23 2015-09-03 주식회사 툴젠 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
KR20150105633A (ko) * 2012-12-12 2015-09-17 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 시스템, 방법 및 최적화된 가이드 조성물의 조작
KR20160050069A (ko) * 2013-09-06 2016-05-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Cas9 변이체 및 그의 용도
WO2017035416A2 (en) * 2015-08-25 2017-03-02 Duke University Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
WO2017083852A1 (en) * 2015-11-13 2017-05-18 MOORE, Tara Methods for the treatment of corneal dystrophies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58255B1 (sr) * 2013-04-16 2019-03-29 Regeneron Pharma Ciljana modifikacija genoma pacova
BR112015031611A2 (pt) 2013-06-17 2017-12-12 Massachusetts Inst Technology aplicação, manipulação e otimização de sistemas, métodos e composições para direcionamento e modelação de doenças e distúrbios de células pós-mitóticas
US20160237455A1 (en) * 2013-09-27 2016-08-18 Editas Medicine, Inc. Crispr-related methods and compositions
KR20160089530A (ko) * 2013-12-12 2016-07-27 더 브로드 인스티튜트, 인코퍼레이티드 Ｈｂｖ 및 바이러스 질병 및 질환을 위한 ｃｒｉｓｐｒ­ｃａｓ 시스템 및 조성물의 전달，용도 및 치료적 적용
JP6799058B2 (ja) 2015-09-21 2020-12-09 アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． アレル選択的な遺伝子編集およびその使用
KR102437228B1 (ko) * 2016-11-14 2022-08-30 주식회사 툴젠 인위적으로 조작된 sc 기능 조절 시스템
MA49610A (fr) * 2016-12-08 2020-05-27 Univ Case Western Reserve Procédés et compositions pour améliorer la production de myéline fonctionnelle

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150101446A (ko) * 2012-10-23 2015-09-03 주식회사 툴젠 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
KR20150105633A (ko) * 2012-12-12 2015-09-17 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 시스템, 방법 및 최적화된 가이드 조성물의 조작
KR20160050069A (ko) * 2013-09-06 2016-05-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Cas9 변이체 및 그의 용도
WO2017035416A2 (en) * 2015-08-25 2017-03-02 Duke University Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
WO2017083852A1 (en) * 2015-11-13 2017-05-18 MOORE, Tara Methods for the treatment of corneal dystrophies

Also Published As

Publication number Publication date
CN111527208A (zh) 2020-08-11
WO2019066490A2 (ko) 2019-04-04
JP7440043B2 (ja) 2024-02-28
EP3690047A2 (en) 2020-08-05
EP3690047A4 (en) 2021-11-03
JP2022023144A (ja) 2022-02-07
CN111527208B (zh) 2024-05-14
AU2018339164A1 (en) 2020-04-09
CA3077153A1 (en) 2019-04-04
RU2020114785A (ru) 2021-10-28
KR20190037145A (ko) 2019-04-05
RU2020114785A3 (ko) 2021-10-28
KR102670361B1 (ko) 2024-05-29
SG11202002130WA (en) 2020-04-29
CN118581083A (zh) 2024-09-03
RU2022103641A (ru) 2022-03-18
BR112020006428A2 (pt) 2020-09-24
AU2018339164B2 (en) 2022-06-16
JP2020536501A (ja) 2020-12-17
RU2767201C2 (ru) 2022-03-16

Similar Documents

Publication Publication Date Title
WO2019066490A3 (ko) 유전자 발현 조절을 위한 인위적인 게놈 조작
EA202090034A1 (ru) Способы модификации сплайсинга рнк
Tallen et al. Keep-ING balance: tumor suppression by epigenetic regulation
WO2017201527A3 (en) Gene therapy methods for age-related diseases and conditions
PH12018501005A1 (en) Oligonucleotides for inducing paternal ube3a expression
WO2015143046A3 (en) Methods and compositions for regulation of zinc finger protein expression
MX2025009778A (es) Composicion farmaceutica de un oligonucleotido antisentido y su uso para el tratamiento del sindrome de angelman
ZA201902226B (en) Aav treatment of huntington's disease
WO2017044857A3 (en) Methods and compositions for the treatment of glaucoma
HK1252970A1 (zh) 确定的多偶联寡核苷酸
MX2020010871A (es) Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia.
MX2017010746A (es) Composicion y metodos para la expresion regulada de un complejo de arn guia/endonucleasa cas.
WO2015153760A3 (en) Methods and compositions for prevention or treatment of a nervous system disorder
WO2015200555A3 (en) Rna modification to engineer cas9 activity
MX2018012556A (es) Composiciones y metodos para programar celulas terapeuticas utilizando nanoportadores de acidos nucleicos dirigidos.
MX2023008504A (es) Inhibidores del factor de crecimiento endotelial vascular (vegf) para usarse en el tratamiento de degeneracion macular humeda.
MX2025000237A (es) Metodos y composiciones para reducir la inmunogenicidad de receptores notch quimericos
EP4249501A3 (en) Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
WO2020104649A3 (en) Novel rna compositions and methods for inhibiting angptl8
ZA202107042B (en) Programmable epigenetic control of gene expression in plants
SG10201907746TA (en) Methods of treating cancer harboring hemizygous loss of tp53
WO2018148071A8 (en) Combination therapy for treating disorders of the ear
EA201790136A1 (ru) Регулирование процессов в биореакторе
MX2020008719A (es) Moléculas de arn en horquilla corto/pequeño.
BR112017012392A2 (pt) supressão de genes remodeladores de cromatina mediada por rnai parental para controlar pragas de insetos hemípteros

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18862957

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020513755

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3077153

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018339164

Country of ref document: AU

Date of ref document: 20180927

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018862957

Country of ref document: EP

Effective date: 20200428

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020006428

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020006428

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200330